Figure 3.

The effect of proteosome inhibitors on the accumulation of HCV core protein variants. (a) Western blotting with anti-core rabbit antibodies after transfection of BHK-21 cells and 24 h incubation (lane 1), and additional 24 h incubation with proteosome inhibitors with subsequent lysis (lanes 2–4); (b) Quantification of images using ImageJ software; signals from the cell cultures treated with proteasome inhibitors were normalized to the signal generated by respective HCV core variant in untreated cells; Y axis shows % stabilization. Data represent the results of two independent experiments. * Core1-152 was better stabilized by epoxomycin treatment than other HCV core forms (p < 0.05); ** core1-98 and core1-60 were not stabilized by epoxomycin treatment as compared to all other HCV core forms (p < 0.05; Tukey–Kramer test).